CORT 108297

Drug Profile

CORT 108297

Alternative Names: ADS-108297; CORT-108297

Latest Information Update: 13 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argenta Discovery; Corcept Therapeutics
  • Developer Corcept Therapeutics
  • Class 3-ring heterocyclic compounds; Obesity therapies; Pyrazoles; Quinolines; Small molecules; Sulfones
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psychiatric disorders; Weight gain

Most Recent Events

  • 30 Sep 2014 Discontinued - Phase-I for Psychiatric disorders (In volunteers) in USA (PO)
  • 30 Sep 2014 Discontinued - Phase-I/II for Weight gain in USA (PO)
  • 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top